Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome

Affiliations

¹ Rajiv Gandhi Cancer Institute and Research Centre, New Delhi 110085, India. Electronic address: halder.rohan@rgcirc.org.
² Rajiv Gandhi Cancer Institute and Research Centre, New Delhi 110085, India.

Comment

Rohan Halder et al. Lancet Haematol. 2023 Jul.

. 2023 Jul;10(7):e487.

doi: 10.1016/S2352-3026(23)00162-X.

¹ Rajiv Gandhi Cancer Institute and Research Centre, New Delhi 110085, India. Electronic address: halder.rohan@rgcirc.org.
² Rajiv Gandhi Cancer Institute and Research Centre, New Delhi 110085, India.

No abstract available

Comment in

Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome - Authors' reply.
Grupp SA; HARMONY trial investigators. Grupp SA, et al. Lancet Haematol. 2023 Jul;10(7):e488-e489. doi: 10.1016/S2352-3026(23)00176-X. Lancet Haematol. 2023. PMID: 37407140 No abstract available.

Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.
Grupp SA, Corbacioglu S, Kang HJ, Teshima T, Khaw SL, Locatelli F, Maertens J, Stelljes M, Stepensky P, Lopez P, Amber V, Pagliuca A, Richardson PG, Mohty M. Grupp SA, et al. Lancet Haematol. 2023 May;10(5):e333-e345. doi: 10.1016/S2352-3026(23)00011-X. Epub 2023 Mar 28. Lancet Haematol. 2023. PMID: 37001534 Clinical Trial.